The ESCEND project has been completed with great success! Based on the exiting results from our phase-II clinical study using fluorescent agents targeting dysplasia and neoplasia and approved for experimental clinical use, ESCEND has advanced evidence on minimally invasive FME, which is on the verge of clinical translation and with immense clinical impact and commercialization potential. FME promises to detect disease earlier, with higher specificity and sensitivity, and stratify disease in terms of cancer progression over the current state of the art. ESCEND provided strong evidence that a hybrid white-light and fluorescence endoscope will become the new BE diagnostic standard.
